Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Key Insights

• Using the 2 Stage Free Cash Flow to Equity, Integra LifeSciences Holdings fair value estimate is US$70.05
• Current share price of US$43.60 suggests Integra LifeSciences Holdings is potentially 38% undervalued
• The US$47.20 analyst price target for IART is 33% less than our estimate of fair value

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Integra LifeSciences Holdings Corporation (NASDAQ:IART) as an investment opportunity by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.

View our latest analysis for Integra LifeSciences Holdings

The Method

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) estimate

	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Levered FCF ($, Millions)	US$269.0m	US$291.0m	US$307.6m	US$321.9m	US$334.4m	US$345.7m	US$356.1m	US$365.9m	US$375.3m	US$384.4m
Growth Rate Estimate Source	Analyst x1	Analyst x1	Est @ 5.71%	Est @ 4.64%	Est @ 3.89%	Est @ 3.37%	Est @ 3.00%	Est @ 2.75%	Est @ 2.57%	Est @ 2.44%
Present Value ($, Millions) Discounted @ 7.6%	US$250	US$251	US$247	US$240	US$232	US$223	US$213	US$204	US$194	US$185

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$2.2b

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.2%. We discount the terminal cash flows to today's value at a cost of equity of 7.6%.

Terminal Value (TV)= FCF₂₀₃₃ × (1 + g) ÷ (r – g) = US$384m× (1 + 2.2%) ÷ (7.6%– 2.2%) = US$7.2b

Present Value of Terminal Value (PVTV)= TV / (1 + r)¹⁰= US$7.2b÷ ( 1 + 7.6%)¹⁰= US$3.5b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$5.7b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$43.6, the company appears quite undervalued at a 38% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

Important Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Integra LifeSciences Holdings as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.6%, which is based on a levered beta of 1.090. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Integra LifeSciences Holdings

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value higher than the current share price? For Integra LifeSciences Holdings, we've compiled three additional factors you should assess:

1. Risks: Case in point, we've spotted 2 warning signs for Integra LifeSciences Holdings you should be aware of, and 1 of them is a bit unpleasant.
2. Future Earnings: How does IART's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
3. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.